In this issue, we bring you insights from Prof. Khaled Musallam and Prof. Aurelio Maggio on their de-LIGHT (longitudinal investigation of genetic and hematologic determinants of outcomes in β-thalassemia) cohort study collaboration.
Thursday, July 2, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Professors Khaled Musallam and Aurelio Maggio share insights from their collaborative de-LIGHT study, which investigates the genetic and hematologic factors influencing outcomes in β-thalassemia. This longitudinal study aims to enhance understanding and treatment approaches for this condition.
Price reaction · baseline $36.82 (2026-07-02T17:53:00.000Z) · hit during market hours · clean, no other AGIO news in the window
day 0 close · peak
+2.1%
Market Sentiment Analysis
POSITIVE FACTORS
Insights from leading experts in the field.
Focus on genetic and hematologic determinants.
Collaboration on a significant cohort study.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+80%
120-day peak, hindsight
Typical move
5%
average across 13 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
Mitapivat
Phase 3 · Transfusion-dependent Alpha-Thalassemia
Full Press Release Details
The post In this issue, we bring you insights from Prof. Khaled Musallam and Prof. Aurelio Maggio on their de-LIGHT (longitudinal investigation of genetic and hematologic determinants of outcomes in β-thalassemia) cohort study collaboration. appeared first on Agios .
Frequently Asked Questions
What is the de-LIGHT study about?
The de-LIGHT study investigates genetic and hematologic factors affecting outcomes in β-thalassemia.
Who are the key researchers in the de-LIGHT study?
Professors Khaled Musallam and Aurelio Maggio are leading the de-LIGHT study.
What is the significance of the de-LIGHT study?
It aims to enhance understanding and treatment of β-thalassemia through longitudinal research.